At ViiV Healthcare our goal is simple; to end the HIV epidemic. Over the last 40 years there have been incredible advances in the development of effective HIV treatments that allow people living with HIV (PLHIV) to suppress their virus to undetectable levels.

However, the needs of PLHIV change over time, and we‘re exploring new ways of treating and preventing HIV through new mechanisms of action and drug delivery.

We have a number of potential medicines in development for the treatment and prevention of HIV:

Clinical development pipeline

Compound number / Generic name / Brand name
Mode of action / Vaccine type 
VH3810109 ✝^ HIV
Phase II
HIV broadly neutralizing antibody
GSK3640254 ^ HIV Phase II HIV maturation inhibitor
GSK1265744 ^
HIV (400 mg/ml formulation) Phase I HIV integrase inhibitor
VH3739937 ^ HIV Phase I HIV maturation inhibitor
VH4004280 ^ HIV Phase I HIV capsid protein inhibitor


An exciting and relatively new area of research in the development of next generation HIV treatments involves broadly neutralising antibodies (bNAbs).

The process of identifying, creating and developing generally well-tolerated and effective innovative HIV therapies is complex and requires ongoing collaboration between research teams that work in many different areas of medicines development.

We’ve got more than 50 active collaborations worldwide with pharmaceutical and biotechnology companies, government agencies, academic institutions and not-for-profit organisations to broaden our capabilities and enhance our performance.


Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.